Format

Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2015;55:489-511. doi: 10.1146/annurev-pharmtox-010611-134654.

Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy.

Author information

1
Department of Biochemistry, University of Zurich, CH-8057 Zurich, Switzerland; email: plueckthun@bioc.uzh.ch.

Abstract

Designed ankyrin repeat proteins (DARPins) can recognize targets with specificities and affinities that equal or surpass those of antibodies, but because of their robustness and extreme stability, they allow a multitude of more advanced formats and applications. This review highlights recent advances in DARPin design, illustrates their properties, and gives some examples of their use. In research, they have been established as intracellular, real-time sensors of protein conformations and as crystallization chaperones. For future therapies, DARPins have been developed by advanced, structure-based protein engineering to selectively induce apoptosis in tumors by uncoupling surface receptors from their signaling cascades. They have also been used successfully for retargeting viruses. In ongoing clinical trials, DARPins have shown good safety and efficacy in macular degeneration diseases. These developments all ultimately exploit the high stability, solubility, and aggregation resistance of these molecules, permitting a wide range of conjugates and fusions to be produced and purified.

KEYWORDS:

directed evolution; protein engineering; protein scaffold; sensors; tumor targeting; virus retargeting

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center